Month: March 2025

– ATH434 is a Disease Modifying Drug Candidate Targeting Parkinsonian Disorders – – Topline Data Expected Mid-Year 2025 – MELBOURNE, Australia and SAN FRANCISCO, March 27, 2025 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the last patient in the ATH434-202 Phase 2 trial has completed the study. The ATH434-202 is an open label study designed to evaluate the safety, efficacy and target engagement of ATH434 in participants with advanced multiple system atrophy (MSA). “Following the positive results from our randomized, double-blind Phase 2 trial1, we are pleased to announce that the last participant has now completed all clinical evaluations in our open-label...

Reference is made to the stock exchange notice on 12 March 2025 where AKVA group ASA (“AKVA”) announced the sale of its 21,55% ownership in Abyss Group AS to Arcus Infrastructure Partners LLP. The transaction was closed today. AKVA’s net proceeds from the sale is approx. MNOK 140 and will result in a positive accounting gain which will be recognized in Q1 2025. The proceeds from the transaction will be used for continued development of AKVA’s core business segments. Dated: 27 March 2025AKVA group ASA Web: www.akvagroup.com CONTACTS:Knut Nesse Chief Executive OfficerPhone: +47 51 77 85 00Mobile: +47 91 37 62 20E-mail: knesse@akvagroup.comRonny Meinkøhn Chief Financial OfficerPhone: +47 51 77 85 00Mobile: +47 98 20 67 76E-mail: rmeinkohn@akvagroup.com*** This information is considered to be inside...

           Record full-year 2024 HIFU revenue of USD 25.7 million, an increase of 15.3% over full-year 2023 Record Q4 2024 HIFU revenue of USD 9.3 million, an increase of 15.0% over Q4 2023 U.S. Focal One HIFU procedures grew 51% on a year-over-year basis in 2024 Focal One receives CE Mark for the treatment of deep infiltrating endometriosis Recent landmark HIFI study publication demonstrates positive outcomes with Focal One® Robotic HIFU versus surgery in the management of prostate cancer First patients treated in Phase I/II study evaluating Focal One Robotic HIFU for the treatment of Benign Prostatic Hyperplasia (BPH) Company to host conference call and webcast today, March 27th, at 8:30 a.m. EDTAUSTIN, Texas, March 27, 2025 – EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, reported today unaudited...

FLORHAM PARK, N.J., March 27, 2025 (GLOBE NEWSWIRE) — BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company developing innovative cancer therapies, today announced that it has filed its annual report on Form 10-K for the fiscal year ended December 31, 2024 with the U.S. Securities and Exchange Commission (“SEC”) on March 27, 2025. The annual report on Form 10-K, which contains the Company’s audited consolidated financial statements, can be accessed on the SEC’s website at www.sec.gov and on the Company’s website at www.beyondspringpharma.com under “Financials & Filings” in the Investors section. The Company will provide a hard copy of its annual report containing its audited consolidated financial statements, free of charge, to its shareholders upon request. Requests...

HONG KONG, March 27, 2025 (GLOBE NEWSWIRE) — UCLOUDLINK GROUP INC. (“UCLOUDLINK” or the “Company”) (NASDAQ: UCL), the world’s first and leading mobile data traffic sharing marketplace, today announced its participation as a sponsor of the LD Micro Invitational XV taking place April 9-10, 2025, at the Westin Grand Central in New York City. Mr. Chaohui Chen, Director and Chief Executive Officer of UCLOUDLINK, and Mr. Yimeng Shi, Chief Financial Officer, will represent the Company and connect with investors, analysts and industry professionals at the conference. Conference participation is by invitation only and registration is mandatory. UCLOUDLINK invites interested parties to register on the conference website in advance. About UCLOUDLINK GROUP INC. UCLOUDLINK is the world’s first and leading mobile data traffic sharing marketplace,...

GREENWICH, Conn., March 27, 2025 (GLOBE NEWSWIRE) — XPO (NYSE: XPO), a leading provider of freight transportation in North America, today announced that its Board of Directors has authorized the repurchase of up to $750 million of XPO’s common stock. The new repurchase plan replaces XPO’s previous share repurchase plan, authorized in February 2019, which had $503 million remaining as of March 26, 2025. The new repurchase plan is effective immediately and permits shares of common stock to be repurchased from time to time at management’s discretion, through a variety of methods, including a 10b5-1 trading plan, open market purchases, privately negotiated transactions, or transactions otherwise in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The timing and number of shares of stock repurchased...